Wall Street bet big against women’s health company after Roe v. Wade ruling
Quick sellers ramped up their bets towards a women’s contraception developer adhering to the U.S. Supreme Court ruling last thirty day period to reverse its landmark Roe v. Wade determination, new data confirmed. According to a report from S&P Global Current market Intelligence revealed Wednesday, small interest in Evofem Biosciences (EVFM) – a pharmaceutical organization that provides females reproductive and contraceptive care merchandise – surged to around 50{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} in the aftermath of the ruling June 24. Limited curiosity in Evofem…